Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression

Reid, AL; Millward, M; Pearce, R; Lee, M; Frank, MH; Ireland, A; Monshizadeh, L; Rai, T; Heenan, P; Medic, S; Kumarasinghe, P; Ziman, M

Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression

Reid, AL Millward, M Pearce, R Lee, M Frank, MH Ireland, A Monshizadeh, L Rai, T

Heenan, P Medic, S Kumarasinghe, P Ziman, M

Permalink

Publication Type:: Journal Article
Citation:: British Journal of Dermatology, 2013, 168 (1), pp. 85 - 92
Issue Date:: 2013-01-01

Closed Access

	Filename	Description	Size
	2012000709OK.pdf		171.22 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Reid, AL	en_US
dc.contributor.author	Millward, M	en_US
dc.contributor.author	Pearce, R	en_US
dc.contributor.author	Lee, M	en_US
dc.contributor.author	Frank, MH	en_US
dc.contributor.author	Ireland, A	en_US
dc.contributor.author	Monshizadeh, L	en_US
dc.contributor.author	Rai, T https://orcid.org/0000-0003-1610-8983	en_US
dc.contributor.author	Heenan, P	en_US
dc.contributor.author	Medic, S	en_US
dc.contributor.author	Kumarasinghe, P	en_US
dc.contributor.author	Ziman, M	en_US
dc.date.issued	2013-01-01	en_US
dc.identifier.citation	British Journal of Dermatology, 2013, 168 (1), pp. 85 - 92	en_US
dc.identifier.issn	0007-0963	en_US
dc.identifier.uri	http://hdl.handle.net/10453/26347
dc.description.abstract	Background Multimarker quantitative real-time polymerase chain reaction (qRT-PCR) represents an effective method for detecting circulating tumour cells in the peripheral blood of patients with melanoma. Objectives To investigate whether the phenotype of circulating melanoma cells represents a useful indicator of disease stage, recurrence and treatment efficacy. Methods Peripheral blood was collected from 230 patients with melanoma and 152 healthy controls over a period of 3 years and 9 months. Clinical data and blood samples were collected from patients with primary melanoma (early stages, 0-II, n = 154) and metastatic melanoma (late stages, III-IV, n = 76). Each specimen was examined by qRT-PCR analysis for the expression of five markers: MLANA, ABCB5, TGFβ2, PAX3d and MCAM. Results In total, 212 of the patients with melanoma (92%) expressed markers in their peripheral blood. Two markers, MLANA and ABCB5, had the greatest prognostic value, and were identified as statistically significant among patients who experienced disease recurrence within our study period, being expressed in 45% (MLANA) and 49% (ABCB5) of patients with recurrence (P = 0·001 and P = 0·031, respectively). For patients administered nonsurgical treatments, MCAM expression correlated with poor treatment outcome. Conclusions Circulating tumour cells were detectable at all stages of disease and long after surgical treatment, even when patients were considered disease free. Specifically, expression of ABCB5 and MLANA had significant prognostic value in inferring disease recurrence, while MCAM expression was associated with poor patient outcome after treatment, confirming multimarker qRT-PCR as a potential technique for monitoring disease status. See also the Commentary by Sullivan © 2012 The Authors. BJD © 2012 British Association of Dermatologists.	en_US
dc.relation.ispartof	British Journal of Dermatology	en_US
dc.relation.isbasedon	10.1111/bjd.12057	en_US
dc.subject.classification	Dermatology & Venereal Diseases	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Melanoma	en_US
dc.subject.mesh	Skin Neoplasms	en_US
dc.subject.mesh	Neoplasm Recurrence, Local	en_US
dc.subject.mesh	Adult	en_US
dc.subject.mesh	Aged	en_US
dc.subject.mesh	Aged, 80 and over	en_US
dc.subject.mesh	Biomarkers, Tumor	en_US
dc.subject.mesh	Case-Control Studies	en_US
dc.subject.mesh	Female	en_US
dc.subject.mesh	Male	en_US
dc.subject.mesh	Middle Aged	en_US
dc.subject.mesh	Neoplastic Cells, Circulating	en_US
dc.subject.mesh	Phenotype	en_US
dc.subject.mesh	Real-Time Polymerase Chain Reaction	en_US
dc.subject.mesh	Treatment Outcome	en_US
dc.subject.mesh	Tumor Burden	en_US
dc.subject.mesh	Young Adult	en_US
dc.title	Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression	en_US
dc.type	Journal Article
utslib.citation.volume	1	en_US
utslib.citation.volume	168	en_US
utslib.for	0104 Statistics	en_US
utslib.for	1103 Clinical Sciences	en_US
utslib.for	1112 Oncology and Carcinogenesis	en_US
dc.location.activity	Sydney NSW
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/DVC (Research)
pubs.organisational-group	/University of Technology Sydney/DVC (Research)/Graduate Research School
utslib.copyright.status	closed_access
pubs.issue	1	en_US
pubs.publication-status	Published	en_US
pubs.volume	168	en_US

Abstract:

Background Multimarker quantitative real-time polymerase chain reaction (qRT-PCR) represents an effective method for detecting circulating tumour cells in the peripheral blood of patients with melanoma. Objectives To investigate whether the phenotype of circulating melanoma cells represents a useful indicator of disease stage, recurrence and treatment efficacy. Methods Peripheral blood was collected from 230 patients with melanoma and 152 healthy controls over a period of 3 years and 9 months. Clinical data and blood samples were collected from patients with primary melanoma (early stages, 0-II, n = 154) and metastatic melanoma (late stages, III-IV, n = 76). Each specimen was examined by qRT-PCR analysis for the expression of five markers: MLANA, ABCB5, TGFβ2, PAX3d and MCAM. Results In total, 212 of the patients with melanoma (92%) expressed markers in their peripheral blood. Two markers, MLANA and ABCB5, had the greatest prognostic value, and were identified as statistically significant among patients who experienced disease recurrence within our study period, being expressed in 45% (MLANA) and 49% (ABCB5) of patients with recurrence (P = 0·001 and P = 0·031, respectively). For patients administered nonsurgical treatments, MCAM expression correlated with poor treatment outcome. Conclusions Circulating tumour cells were detectable at all stages of disease and long after surgical treatment, even when patients were considered disease free. Specifically, expression of ABCB5 and MLANA had significant prognostic value in inferring disease recurrence, while MCAM expression was associated with poor patient outcome after treatment, confirming multimarker qRT-PCR as a potential technique for monitoring disease status. See also the Commentary by Sullivan © 2012 The Authors. BJD © 2012 British Association of Dermatologists.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/26347